USPTO serial 90042373
DXT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- KERTGATE, AMY L
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DXT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kristen McCallion
Kristen McCallion FISH & RICHARDSON P.C.P.O. BOX 1022MINNEAPOLIS, MN 55440-1022UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceutical preparations; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of rare ocular disorders or diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold preparations; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treatment of rare tissue and organ transplantation-related diseases and conditions; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems | ACTIVE | — |
| 009 | downloadable computer software for use in identifying new drugs; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable computer application software for mobile phones, namely, software for use in identifying new drugs; downloadable computer software using artificial intelligence for use in identifying new drugs; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems | ACTIVE | — |
| 042 | software as a service (SAAS) services featuring software using artificial intelligence for use in identifying new drugs; providing a website featuring non-downloadable software using artificial intelligence for use in identifying new drugs; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of virtual reality software for medical teaching | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by DOMPÉ FARMACEUTICI SPA
- Other trademarks owned by DOMPÉ FARMACEUTICI SPA
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named DXT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 6, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 5, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 4, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 2, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 2, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 2, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 3, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 24, 2021 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jun 3, 2021 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 2, 2021 | APET | ASSIGNED TO PETITION STAFF | — |
| May 25, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 25, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 29, 2021 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jan 8, 2021 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 15, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 15, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 25, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 9, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 7, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 16, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 6, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 11, 2020 | NWAP | NEW APPLICATION ENTERED | — |